Postdoctoral Fellow - Dr. Shengqing (Stan) Gu, Dept. of Hematopoietic Biology and Malignancy
Job posting number: #7115324
Posted: November 2, 2022
Application Deadline: Open Until Filled
Job DescriptionA Postdoctoral position is available in the Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. This position reports to Dr. Shengqing (Stan) Gu in the Department of Hematopoietic Biology and Malignancy.
We are seeking a talented and highly motivated Postdoctoral Fellow with a strong biomedical research background to study the regulation of cancer-immune interactions, such as cancer antigen presentation. The postdoctoral fellow will conduct research integrating various cutting-edge experimental and computational approaches, such as functional genomics, single cell / spatial multi-omics, data mining, machine learning, and mathematical modeling, with the goal of translating findings to clinically meaningful advances. More information on the research interests of the Gu lab can be found at: https://scholar.harvard.edu/sgu/research
The fellow will receive training and conduct research at the broad intersection of cancer immunology and computational biology, which will help build a strong portfolio for their future career development. The fellow will work closely with local experimental and/or computational collaborators in seeking to enhance the efficacy of cancer immunotherapy, such as by modulating cancer antigen presentation. The fellow will also benefit from collaborations with former colleagues of Dr. Gu at many institutes.
Dr. Gu graduated from University of Toronto with a PhD in Medical Biophysics, did postdoctoral training at Harvard Medical School and Dana-Farber Cancer Institute, and has excellent track record in highly collaborative and interdisciplinary research in cancer biology, immunology, and computational biology:
Leukemia biology: (Gu, Chan, Mohi et al., Blood, 2016; Gu et al., Leukemia, 2018)
Cancer immunology: (Jiang, Gu, Pan et al., Nature Medicine, 2018; Gu, Wang, Hu et al., Genome Biology, 2020; Shi, Gu et al., Clinical Cancer Research, 2020; Gu, Zhang, Wang, Jiang et al., Cancer Discovery, 2021; Wang, Tokheim, Gu, Wang et al., Cell, 2021; Zeng, Gu et al., Cancer Immunology Research, accepted)
Computational biology: (Gu et al., PNAS, 2021; Zeng, Gu et al., Science Advances, accepted)
Dr. Gu is strongly committed to the professional fulfillment and career advancement of all trainees. He will work on creating a successful transition plan to academia or industry for the fellow in accordance with their evolving preferences. The fellow will have access to the rich research platforms at MD Anderson and more broadly the Texas Medical Center, including computation cluster, single-cell core facility, epigenetics core facility, flow cytometry facilities, drug screening core, animal colony, among many others.
Highly motivated individuals with a PhD degree in Biology, Bioinformatics, Computer Science, or related areas are encouraged to apply. Candidate should have strong organizational skills and the ability to prioritize and manage multiple projects. Proven track record of publications, excellent written and oral communication skills are required.
Field of study for the degree required: Biology, Bioinformatics, Computer Science, or related areas
Application Deadline: Consideration of applications will begin immediately and continue until the position is filled.
*Stipend: Stipend support will follow the NIH Kirschstein-NRSA stipend levels level for the appropriate PGY.
It is the policy of The University of Texas MD Anderson Cancer Center to provide equal employment opportunity without regard to race, color, religion, age, national origin, sex, gender, sexual orientation, gender identity/expression, disability, protected veteran status, genetic information, or any other basis protected by institutional policy or by federal, state or local laws unless such distinction is required by law. http://www.mdanderson.org/about-us/legal-and-policy/legal-statements/eeo-affirmative-action.html